학술논문
Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
Document Type
Article
Author
Arakelyan, Nina; Jais, Jean-Philippe; Tomowiack, Cécile; Colombat, Philippe; Berthou, Christian; Desablens, Bernard; Moles-Moreau, Marie-Pierre; Gastinne, Thomas; Quittet, Philippe; Casassus, Philippe; Le Pourhiet-Le Mevel, Annick; Ghandour, Christiane; Brière, Josette; Colonna, Pierre; Andrieu, Jean-Marie
Source
Subject
*HODGKIN'S disease treatment
*DOXORUBICIN
*BLEOMYCIN
*DISEASE remission
*CANCER chemotherapy
*
*
*
*
Language
ISSN
1042-8194
Abstract
The H97-I trial (1997-2004) for Hodgkin lymphoma at intermediate stage (HL-I) included 269 patients who were randomized to receive three or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). The 197 patients who reached complete remission (CR) (73.2%, p = 0.41 between arms) received radiotherapy (RT); their 10-year progression-free survival (PFS) rate was 87.7 ± 3.0%, similar to that of the 180 patients of a historical control group (HCG) in CR after three ABVD cycles before RT. The 59 patients who reached post-ABVD partial remission (PR) received one course of intensive chemotherapy (i.v., mg/m2, vindesine 5, adriamycin 90, BCNU 140, etoposide 600, methylprednisolone 600) before RT. In spite of this additional intensive chemotherapy, their PFS rate (78.4 ± 6.3%) remained significantly lower ( p = 0.03) than that of the 197 patients who reached post-ABVD CR, and was similar to that of the 60 patients of the HCG in PR after three ABVD cycles who did not receive additional chemotherapy before RT. [ABSTRACT FROM AUTHOR]